Skip to main content

Generex (GNBT) - decent buy signal

Here is a view of what the system looks like. Note the red peak in the lower chart. This indicates that a low has been hit. The horizontal green line intersects the red peak. Where it intersects on the right side of the peak (the trailing edge, as the engineers would say), we have a Buy signal. This Buy signal is clearly earlier than that provided by the 20-day EMA moving above the 50-day EMA, for example. That is the benefit this system attempts to provide, an earlier signal that is still reliable.

To make it interesting, I did put a few dollars on this one though a bit later than the date the system indicated. I consider this signal to be "decent" because the peak is kind of sloppy at the bottom which also causes my Signal-to-Noise indicator to be a bit weak. In any case, if you had bought when the signal indicated (at $1.69 on 8/24/06), you'd be sitting on a 20% profit today, two and a half months after entering the trade.

I'll provide more information on the confirming signal statistics in later posts.

Comments

Anonymous said…
Today’s GNBT’s announcement of Craig Eagle, M.D. to its scientific advisory board is an important move.
Dr. Eagle’s connection with Pfizer is GNBT’s first step toward partnership with Pfizer.
This partnership will open a huge market to GNBT and give Pfizer access to products it does not have.
GNBT is very close to get the FDA approval for its drug delivery system and is going to need Pfizer like company to help put it on the map. Great move by GNBT.

Popular posts from this blog

Trade Radar gets another update

Some of our data sources changed again and it impacted our ability to load fundamental/financial data. In response, we are rolling out a new version of the software: 7.1.24 The data sourcing issues are fixed and some dead links in the Chart menu were removed. So whether you are a registered user or someone engaged in the free trial, head over to our update page and download the latest version. The update page is here:   https://tradingstockalerts.com/software/downloadpatch Contact us if you have questions or identify any new issues.

Unlock Stock Market Profits - Key #4

This is the fourth article in a series of posts describing 10 tools to help you identify and evaluate good investing ideas. It is based on a post that provides a summary of the ten keys that individual investors should use to identify profitable stock trades. ( Click here to read the original post ) With this fourth post, we will continue another step along the path of finding stocks that seem to have some potential. The first post in the series discussed how to use unusual activity to identify investing ideas. The second post described how to use stock screeners. The third post described how to use lists of new highs and new lows. This post will focus on identifying social or business trends in order to find investing ideas. Information on new trends might turn up anywhere. In conversation with friends or business associates, in newspapers or magazines, on TV or though your work. The key is to be aware of trends and how they start, stop or change. We'll start by describing what...

Business Intelligence consolidation - who's next?

We have seen a consolidation wave begin in the Business Intelligence space. IBM just bought Cognos and Oracle recently bought Hyperion. SAP just announced they are buying Business Objects after barely having time to digest their recent acquisition of Pilot Software. There are three major database vendors at this time: IBM with their DB2 product, Oracle with their flagship Oracle database and Microsoft with their SQL Server database. IBM and Oracle now have premier, industrial-strength data analysis and reporting products in their product portfolios that complement their core database products. Microsoft has what, Excel? Actually, Microsoft, like IBM and Oracle, has a suite of proprietary tools that do happen to integrate very well with Excel and SQL Server. Still, IT departments are not deploying the Microsoft tools for heavy-duty corporate use. Microsoft is unique among the big three by their lack of a premier reporting product. It seems safe to assume that Microsoft will be the next...